{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:13:28Z","timestamp":1792620808987,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40264-024-01454-0","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T06:01:52Z","timestamp":1721023312000},"page":"1039-1049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Pregnancy Outcomes in Patients Treated with Upadacitinib: Analysis of Data from Clinical Trials and Postmarketing Reports"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-8061","authenticated-orcid":false,"given":"Uma","family":"Mahadevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gweneth","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianne","family":"Gensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana P.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lani","family":"Wegrzyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Palac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Bhutani-Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Millie","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E. B.","family":"Clowse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa B.","family":"Kimball","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Scialli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"key":"1454_CR1","unstructured":"AbbVie Inc. Rinvoq\u00ae prescribing information. Updated May 2023."},{"issue":"8","key":"1454_CR2","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","volume":"158","author":"WJ Sandborn","year":"2020","unstructured":"Sandborn WJ, Feagan BG, Loftus EV Jr, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease. Gastroenterology. 2020;158(8):2123-38.e8. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.047.","journal-title":"Gastroenterology"},{"issue":"5","key":"1454_CR3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","volume":"30","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30(5):779\u201387. https:\/\/doi.org\/10.1080\/14397595.2020.1782049.","journal-title":"Mod Rheumatol"},{"issue":"1","key":"1454_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, Nakasato P, Wung P. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1): e13688. https:\/\/doi.org\/10.1111\/cts.13688.","journal-title":"Clin Transl Sci"},{"issue":"5","key":"1454_CR5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/acr.20422","volume":"63","author":"B Kuriya","year":"2011","unstructured":"Kuriya B, Hernandez-Diaz S, Liu J, et al. Patterns of medication use during pregnancy in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(5):721\u20138. https:\/\/doi.org\/10.1002\/acr.20422.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"1454_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.reprotox.2015.10.015","volume":"58","author":"AR Scialli","year":"2015","unstructured":"Scialli AR, Bailey G, Beyer BK, et al. Potential seminal transport of pharmaceuticals to the conceptus. Reprod Toxicol. 2015;58:213\u201321. https:\/\/doi.org\/10.1016\/j.reprotox.2015.10.015.","journal-title":"Reprod Toxicol"},{"key":"1454_CR7","unstructured":"National Center for Health Statistics, Centers for Disease Control and Prevention. Data table of infant weight-for-age charts. 2001. https:\/\/www.cdc.gov\/growthcharts\/html_charts\/wtageinf.htm#print. Accessed 18 Jun 2024."},{"key":"1454_CR8","unstructured":"United Kingdom-World Health Organization (WHO). UK-WHO growth charts: neonatal and infant close monitoring (NICM). 2009. https:\/\/www.rcpch.ac.uk\/resources\/uk-who-growth-charts-neonatal-infant-close-monitoring-nicm. Accessed 18 Jun 2024."},{"key":"1454_CR9","volume-title":"WHO recommendations for care of the preterm or low birth weight infant","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. WHO recommendations for care of the preterm or low birth weight infant. Geneva: World Health Organization; 2022."},{"key":"1454_CR10","unstructured":"United Nations Children's Fund (UNICEF), World Health Organization (WHO). UNICEF-WHO Low birthweight estimates: levels and trends 2000\u20132015. New York, NY: UNICEF and WHO; 2019."},{"issue":"3","key":"1454_CR11","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.semarthrit.2021.04.003","volume":"51","author":"Y Meissner","year":"2021","unstructured":"Meissner Y, Rudi T, Fischer-Betz R, Strangfeld A. Pregnancy in women with psoriatic arthritis: a systematic literature review of disease activity and adverse pregnancy outcomes. Semin Arthritis Rheum. 2021;51(3):530\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2021.04.003.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1454_CR12","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.autrev.2018.08.008","volume":"18","author":"L Andreoli","year":"2019","unstructured":"Andreoli L, Gerardi MC, Fernandes M, et al. Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. Autoimmun Rev. 2019;18(2):164\u201376. https:\/\/doi.org\/10.1016\/j.autrev.2018.08.008.","journal-title":"Autoimmun Rev"},{"issue":"7","key":"1454_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s41584-019-0240-8","volume":"15","author":"I Giles","year":"2019","unstructured":"Giles I, Yee CS, Gordon C. Stratifying management of rheumatic disease for pregnancy and breastfeeding. Nat Rev Rheumatol. 2019;15(7):391\u2013402. https:\/\/doi.org\/10.1038\/s41584-019-0240-8.","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"1454_CR14","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/cpt.2602","volume":"113","author":"CJ Bowman","year":"2023","unstructured":"Bowman CJ, Becourt-Lhote N, Boulifard V, et al. Science-based approach to harmonize contraception recommendations in clinical trials and pharmaceutical labels. Clin Pharmacol Ther. 2023;113(2):226\u201345. https:\/\/doi.org\/10.1002\/cpt.2602.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1454_CR15","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s40264-016-0431-z","volume":"39","author":"ME Clowse","year":"2016","unstructured":"Clowse ME, Feldman SR, Isaacs JD, et al. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug Saf. 2016;39(8):755\u201362. https:\/\/doi.org\/10.1007\/s40264-016-0431-z.","journal-title":"Drug Saf"},{"key":"1454_CR16","unstructured":"Centers for Disease Control and Prevention. Birth defects are common, costly, and critical. Atlanta, GA: CDC; 2023."},{"key":"1454_CR17","doi-asserted-by":"publisher","first-page":"175628482110162","DOI":"10.1177\/17562848211016242","volume":"14","author":"R Laube","year":"2021","unstructured":"Laube R, Paramsothy S, Leong RW. Review of pregnancy in Crohn\u2019s disease and ulcerative colitis. Ther Adv Gastroenterol. 2021;14:17562848211016242. https:\/\/doi.org\/10.1177\/17562848211016242.","journal-title":"Ther Adv Gastroenterol"},{"issue":"12","key":"1454_CR18","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/ibd\/izy160","volume":"24","author":"U Mahadevan","year":"2018","unstructured":"Mahadevan U, Dubinsky MC, Su C, et al. Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflamm Bowel Dis. 2018;24(12):2494\u2013500. https:\/\/doi.org\/10.1093\/ibd\/izy160.","journal-title":"Inflamm Bowel Dis"},{"issue":"18","key":"1454_CR19","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/bdr2.1589","volume":"111","author":"CT Mai","year":"2019","unstructured":"Mai CT, Isenburg JL, Canfield MA, et al. National population-based estimates for major birth defects, 2010\u20132014. Birth Defects Res. 2019;111(18):1420\u201335. https:\/\/doi.org\/10.1002\/bdr2.1589.","journal-title":"Birth Defects Res"},{"key":"1454_CR20","unstructured":"Menillo AM, Lee LS, Pearson-Shaver AL. Atrial septal defects: Treasure Island (FL): StatPearls Publishing; 2024 [updated August 7, 2023]. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK535440\/. Accessed 18 Jun 2024."},{"key":"1454_CR21","unstructured":"Dugas C, Slane V. Miscarriage. In: StatPearls. Treasure Island (FL): StatPearls Publishing; updated 2022 May 8."},{"issue":"9","key":"1454_CR22","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3899\/jrheum.141553","volume":"42","author":"M Wallenius","year":"2015","unstructured":"Wallenius M, Salvesen KA, Daltveit AK, Skomsvoll JF. Miscarriage and stillbirth in women with rheumatoid arthritis. J Rheumatol. 2015;42(9):1570\u20132. https:\/\/doi.org\/10.3899\/jrheum.141553.","journal-title":"J Rheumatol"},{"issue":"4","key":"1454_CR23","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2796.2010.02239.x","volume":"268","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Larsson H, Pedersen L, et al. Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study. J Intern Med. 2010;268(4):329\u201337. https:\/\/doi.org\/10.1111\/j.1365-2796.2010.02239.x.","journal-title":"J Intern Med"},{"issue":"9","key":"1454_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1111\/j.1468-3083.2010.03917.x","volume":"25","author":"E Cohen-Barak","year":"2011","unstructured":"Cohen-Barak E, Nachum Z, Rozenman D, Ziv M. Pregnancy outcomes in women with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2011;25(9):1041\u20137. https:\/\/doi.org\/10.1111\/j.1468-3083.2010.03917.x.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"9","key":"1454_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/apt.15654","volume":"51","author":"HH Lee","year":"2020","unstructured":"Lee HH, Bae JM, Lee BI, et al. Pregnancy outcomes in women with inflammatory bowel disease: a 10-year nationwide population-based cohort study. Aliment Pharmacol Ther. 2020;51(9):861\u20139. https:\/\/doi.org\/10.1111\/apt.15654.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"1454_CR26","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.jogc.2016.01.002","volume":"38","author":"D Costescu","year":"2016","unstructured":"Costescu D, Guilbert E, Bernardin J, et al. Medical abortion. J Obstet Gynaecol Can. 2016;38(4):366\u201389. https:\/\/doi.org\/10.1016\/j.jogc.2016.01.002.","journal-title":"J Obstet Gynaecol Can"},{"issue":"10","key":"1454_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186487","volume":"12","author":"HE Jones","year":"2017","unstructured":"Jones HE, O\u2019Connell White K, Norman WV, et al. First trimester medication abortion practice in the United States and Canada. PLoS\u00a0One. 2017;12(10): e0186487. https:\/\/doi.org\/10.1371\/journal.pone.0186487.","journal-title":"PLoS\u00a0One"},{"issue":"5","key":"1454_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1136\/ard.2010.140822","volume":"70","author":"SM Verstappen","year":"2011","unstructured":"Verstappen SM, King Y, Watson KD, et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(5):823\u20136. https:\/\/doi.org\/10.1136\/ard.2010.140822.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1454_CR29","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.38368","volume":"66","author":"C Weber-Schoendorfer","year":"2014","unstructured":"Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66(5):1101\u201310. https:\/\/doi.org\/10.1002\/art.38368.","journal-title":"Arthritis Rheumatol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01454-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01454-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T16:04:31Z","timestamp":1726243471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01454-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1454"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01454-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"30 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work\/study was funded by AbbVie Inc. AbbVie participated in the study design, research, data collection, analysis and interpretation of data, writing, reviewing, and approving the publication. All authors had access to the data results, and participated in the development, review, and approval of this paper. No honoraria or payments were made for authorship.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Uma Mahadevan has received consultant fees from AbbVie, Bristol Myers Squibb, Boeringher Ingelheim, Celltrion, Enveda, Gilead, Janssen, Lilly, Pfizer, Protagonist, Roivant, and Takeda; has served on the data and safety monitoring board for Merck and Prometheus Bioscienes; has served on the scientific advisory board for Rani Therapeutics; and has received research funding from the Helmsley Charitable Trust. Anthony R. Scialli has received consulting fees from AbbVie. Millie Long has received consultant fees from AbbVie, Janssen, Pfizer, Lilly, Takeda, BMS, Prometheus, Intercept, and Target RWE and has received research support from Takeda, Lilly, and Pfizer. Alexa B. Kimball has received consulting fees from AbbVie, Alumis, Bayer, Boehringer Ingelheim, Eli Lilly, Evoimmune, Janssen, Novartis, Moonlake, Pfizer, Priovant, Sanofi, Sonoma Bio, Target RWE, UCB, Union Therapeutics, Ventyx, Janssen, Meiji, LEO, and Concert Pharmaceuticals and serves on the board of directors for Almirall and University of California, San Diego-led pregnancy registries. Her institution has received grants from AbbVie, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, Novartis, Pfizer, Sanofi, Sonoma Bio, and UCB. Tina Bhutani-Jacques is currently a principal investigator for studies being sponsored by Amgen, Castle, CorEvitas, Pfizer, and Regeneron. She has received additional research funding from Novartis and has served as an advisor for AbbVie, Arcutis, Boehringer-Ingelheim, Bristol Myers Squibb, Dermavant, Janssen, Leo, Lilly, Pfizer, Novartis, Sanofi, Sun, and UCB. Gweneth Levy, Mira Ali, Ana P. Lacerda, Lani Wegrzyn, and Hannah Palac are employees of AbbVie and may own stock or stock options. Megan E.B. Clowse has received consulting fees from UCB and GSK, research grant funding from GSK, educational grant funding from UCB and GSK, and serves on review boards for University of California, San Diego-led pregnancy registries. Christina Chambers receives research funding from the following industry sponsors and a foundation: Amgen, AstraZeneca, GlaxoSmithKline, Janssen Pharmaceuticals, Pfizer, Regeneron, Hoffman La-Roche-Genentech, Genzyme Sanofi-Aventis, Takeda Pharmaceutical Company Limited, Sanofi, UCB Pharma USA, Leo Pharma, Sun Pharma Global FZE, Gilead, Novartis, and the Gerber Foundation. Lianne Gensler has received grants from Novartis and UCB Pharma paid to her institution and consulting fees from AbbVie, Fresenius Kabi, Gilead, Janssen, Eli Lilly, MoonLake, Novartis, Pfizer, and UCB Pharma.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Each individual trial included in this report was conducted in accordance with the ethical principles that have their origin in the current Declaration of Helsinki and was consistent with International Conference on Harmonization Good Clinical Practice, Good Epidemiology Practices, and applicable regulatory requirements. Each individual trial included in this report was approved by an independent ethics committee\/institutional review board at each study site (ESM). Initial submission of unsolicited postmarketing reports by physicians or patients is voluntary. For the collection of further information after the initial report, a reporter\u2019s consent was obtained through a query in the global safety database. Authors had access to de-identified anonymized data to prepare this report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before enrolling in each clinical trial.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was sponsored by AbbVie. AbbVie and the authors are committed to responsible data sharing regarding clinical trial participation. This includes access to anonymized, individual, and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), provided the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications. Studies are available for sharing when all the following criteria are met: 12 months after the global end of the trial date, after the studied product and indication have been approved by regulatory authorities in the following countries\/regions: USA and European Union, USA or European Union (when regulatory submissions in both regions are not planned), other country (when US or European Union regulatory submissions are not planned), the study is not part of an ongoing or planned regulatory submission in the regions listed above, and after the primary manuscript describing the results has been accepted for publication. AbbVie may choose to proactively share studies beyond the criteria noted above. For more information on the process, or to submit a request, visit the following link: .","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the interpretation of data and drafting and revising of the publication. GL and HP substantially contributed to the acquisition of data and data analysis. GL and MA substantially contributed to the study conception and design. Substantial contributions to conception and design: GL, MA. Acquisition of data: GL, HP. Data analysis: GL, HP. Interpretation of data: UM, LG, GL, MA, APL, LW, HP, TB-J, ML, MEBC, ABK, CC, ARS. Involved in drafting\/revising critically for intellectual content: UM, LG, GL, MA, APL, LW, HP, TB-J, ML, MEBC, ABK, CC, ARS.\u00a0All authors read and approved the final version.\u00a0","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}